Molecular characteristics of high-dose melphalan associated oral mucositis in patients with multiple myeloma: A gene expression study on human mucosa

PLoS ONE

Volumn 12, Issue 1, 2017, Pages

  Marcussen, Mette ^a,b   Bødker, Julie Støve ^b   Christensen, Heidi Søgaard ^b   Johansen, Preben ^b   Nielsen, Søren ^b   Christiansen, Ilse ^b   Bergmann, Olav Jonas ^c   Bøgsted, Martin ^a,b   Dybkær, Karen ^a,b   Vyberg, Mogens ^a,b   Johnsen, Hans Erik ^a,b  

^a AALBORG UNIVERSITY   (Denmark)

^b AALBORG UNIVERSITY HOSPITAL   (Denmark)

^c AARHUS UNIVERSITY   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIFUNGAL AGENT; ANTIINFECTIVE AGENT; ANTIVIRUS AGENT; BORTEZOMIB; CYCLOPHOSPHAMIDE; DENDRITIC CELL LYSOSOME ASSOCIATED MEMBRANE PROTEIN; DEXAMETHASONE; HLA DRB1 ANTIGEN; HLA DRB5 ANTIGEN; MELPHALAN; PROTEIN MDM2; PROTEIN P53; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; TRIGGERING RECEPTOR EXPRESSED ON MYELOID CELLS 2; TUMOR NECROSIS FACTOR;

ADULT; AGED; APOPTOSIS; ARTICLE; BACTERIAL INFECTION; BUCCAL MUCOSA; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DENDRITIC CELL; DISEASE MARKER; DISEASE SEVERITY; DRUG MEGADOSE; FEMALE; GENE; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; HISTOPATHOLOGY; HLA DRB1 GENE; HLA DRB5 GENE; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREGULATION; INPPD5 GENE; LAMP3 GENE; MALE; MDM2 GENE; MIDDLE AGED; MUCOSA; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; MYCOSIS; OPPORTUNISTIC INFECTION; ORAL MUCOSITIS; TIGAR GENE; TREM2 GENE; UPREGULATION; VERY ELDERLY; VIRUS INFECTION; BIOPSY; BLOOD; CHEMICALLY INDUCED; DOSE RESPONSE; FOLLOW UP; GENETICS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; IMMUNOLOGY; METABOLISM; MOUTH MUCOSA; PATHOLOGY; STOMATITIS;

AGED; BIOPSY; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FOLLOW-UP STUDIES; GENE EXPRESSION REGULATION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HLA-DRB5 CHAINS; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MELPHALAN; MIDDLE AGED; MOUTH MUCOSA; MULTIPLE MYELOMA; STOMATITIS;

EID: 85008339421     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0169286     Document Type: Article

References (62)

1. Moreau P, Attal M, Facon T. Frontline therapy of multiple myeloma. Blood 2015; 125:3076-84. doi: 10.1182/blood-2014-09-568915 PMID: 25838345
2. Blijlevens N, Schwenkglenks M, Bacon P., D'Addio A, Einsele H, Maertens J., et al. Prospective oral mucositis audit: oral mucositis in patients receiving high-dose melphalan or BEAM conditioning chemotherapy. European Blood and Marrow Transplantation Mucositis Advisory Group. J Clin Oncol 2008; 26:1519-25. doi: 10.1200/JCO.2007.13.6028 PMID: 18268357
3. Elting LS, Cooksley C, Chambers M., Cantor SB, Manzullo E, Rubenstein EB. The burdens of cancer therapy. Clinical and economic outcomes of chemotherapy-induced mucositis. Cancer 2003; 98:1531-9. doi: 10.1002/cncr.11671 PMID: 14508842
4. Chen Y-K, Hou H., Chow J-M, Chen Y-C, Hsueh P-R, Tien H-F. The impact of oral herpes simplex virus infection and candidiasis on chemotherapy-induced oral mucositis among patients with hematological malignancies. Eur J Clin Microbiol Infect Dis 2011; 30:753-9. doi: 10.1007/s10096-010-1148-z PMID: 21225303
5. McCann S, Schwenkglenks M, Bacon P., D'Addio A, Einsele H, Maertens J., et al. The Prospective Oral Mucositis Audit: relationship of severe oral mucositis with clinical and medical resource use outcomes in patients receiving high-dose melphalan or BEAM-conditioning chemotherapy and autologous SCT. Bone Marrow Transplant 2009; 43:141-7. doi: 10.1038/bmt.2008.299 PMID: 18776926
6. Lalla RV, Bowen J, Barasch A., Elting L, Epstein J, Keefe D.M., et al. MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy. Cancer 2014; 120:1453-61. doi: 10.1002/cncr.28592 PMID: 24615748
7. Gibson RJ, Keefe DMK, Lalla RV, Bateman E, Blijevens N., Fijlstra M, et al. Systematic review of agents for the management of gastrointestinal mucositis in cancer patients. Support Care Cancer 2013; 21:313-26. doi: 10.1007/s00520-012-1644-z PMID: 23142924
8. Gkotzamanidou M, Sfikakis PP, Kyrtopoulos S.A., Bamia C., Dimopoulos MA, Soulitis VL. Cromatin structure, transcriptional activity and DNA repair efficiency affects the outcome of chemotherapy in multiple myeloma. Br J Cancer 2014; 23:1293-304.
9. Nath CE, Shaw PJ, Trotman J, Zeng L., Duffull SB, Hegarty G, et al. Population pharmacokinetics of melphalan in patients with multiple myeloma undergoing high dose therapy. Br J Clin Pharmacol 2010; 69:484-97. doi: 10.1111/j.1365-2125.2010.03638.x PMID: 20573084
10. Sonis ST. The pathobiology of mucositis. Nat Rev Cancer 2004; 4:277-84. doi: 10.1038/nrc1318 PMID: 15057287
11. Bowen JM, Gibson RJ, Keefe D.M., Cummins AG. Cytotoxic chemotherapy upregulates pro-apoptotic Bax and Bak in the small intestine of rats and humans. Pathology 2005; 37:56-62. PMID: 15875735
12. Bowen JM, Gibson RJ, Cummins A.G., Keefe DMK. Intestinal mucositis: The role of the Bcl-2 family, p53 and caspases in chemotherapy-induced damage. Support Care Cancer 2006; 14:713-31. doi: 10.1007/s00520-005-0004-7 PMID: 16453135
13. Logan RM, Gibson RJ, Bowen J.M., Stringer AM, Sonis ST, Keefe DMK. Characterisation of mucosal changes in the alimentary tract following administration of irinotecan: implications for the pathobiology of mucositis. Cancer Chemother Pharmacol 2008; 62:33-41. doi: 10.1007/s00280-007-0570-0 PMID: 17703303
14. Bowen JM, Gibson RJ, Tsykin A, Stringer A.M., Logan RM, Keefe DMK. Gene expression analysis of multiple gastrointestinal regions reveals activation of common cell regulatory pathways following cytotoxic chemotherapy. Int J Cancer 2007; 121:1847-56. doi: 10.1002/ijc.22895 PMID: 17594691
15. Logan RM, Gibson RJ, Sonis S.T., Keefe DMK. Nuclear factor-kappaB (NF-kappaB) and cyclooxygen-ase-2 (COX-2) expression in the oral mucosa following cancer chemotherapy. Oral Oncol 2007; 43:395-401. doi: 10.1016/j.oraloncology.2006.04.011 PMID: 16979925
16. Stringer AM, Al-Dasooqi N, Bowen J.M., Tan TH, Radzuan M, Logan RM, et al. Biomarkers of chemotherapy-induced diarrhoea: A clinical study of intestinal microbiome alterations, inflammation and circulating matrix metalloproteinases. Support Care Cancer 2013; 21:1843-52. doi: 10.1007/s00520-013-1741-7 PMID: 23397098
17. Sonis S, Antin J, Tedaldi M., Alterovitz G. SNP-based Bayesian networks can predict oral mucositis risk in autologous stem cell transplant recipients. Oral Dis 2013; 19:721-7. doi: 10.1111/odi.12146 PMID: 23809011
18. Coleman EA, Lee JY, Erickson S.W., Goodwin JA, Sanathkumar N, Raj VR, et al GWAS of 972 autologous stem cell recipients with multiple myeloma identifies 11 genetic variants associated with chemotherapy-induced oral mucositis. Support Care Cancer 2014; 23:841-9. doi: 10.1007/s00520-014-2406-x PMID: 25218607
19. Rajkumar SV, Dimopoulos MA, Palumbo A, Blade J., Merlini G, Mateos MV, et al International myeloma group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol 2014; 15:e538-48. doi: 10.1016/S1470-2045(14)70442-5 PMID: 25439696
20. Quinn B, Stone R, Uhlenhopp M., McCann S, Blijlevens N. Ensuring accurate oral mucositis assessment in the European Group for Blood and Marrow Transplantation Prospective Oral Mucositis Audit. Eur J Oncol Nurs 2007; 11:s10-11. doi: 10.1016/S1462-3889(07)70003-0 PMID: 17540294
21. Common terminology criteria for adverse events (CTCAE). U:S: Department of Health and Human Services, National Institutes of health, National Cancer Institute. http://evs.nci.nih.gov/ftp1/CTCAE/CTCAE-4.03-2010-06-14-QuickReference-5x7.pdf
22. Lee MLT, Whitmore GA Power and sample size for DNA microarray studies. Statist Med 2002; 21:3543-70.
23. R Core Team. A Language and Environment for Statistical Computing. R Foundation for Statistical Computing, 2012, Vienna, Austria. http://R-project.org
24. Gentleman RC, Carey VJ, Bates D.M., Bolstad B., Dettling M, Dudoit S, et al Bioconductor: open software development for computational biology and bioinformatics. Genome Biol 2004; 5:R80. doi: 10.1186/gb-2004-5-10-r80 PMID: 15461798
25. Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc 1995; 57:289-300.
26. Dai M, Wang P, Boyd A.D., Kostov G., Athey B, Jones EG, et al Evolving gene/transcript definitions significantly alter the interpretation of GeneChip data. Nucleic Acids Res 2005; 33:1-9.
27. Smyth G. Linear models and empirical bayes methods for assessing differential expression in microarray experiments. Stat Appl Genet Mol Biol 2004; 3:1-25.
28. Durie BGM, Harousseau JL, Miguel J.S., Blade J., Barlogie B, Anderson K, et al International uniform response criteria for multiple myeloma. Leukemia 2006; 20:1467-73. doi: 10.1038/sj.leu.2404284 PMID: 16855634
29. Podar K, Raab MS, Tonon G, Sattler M., Barilà D, Zhang J, et al. Up-regulation of c-Jun inhibits proliferation and induces apoptosis via caspase-triggered c-Abl cleavage in human multiple myeloma. Cancer Res 2007; 67:1680-8. doi: 10.1158/0008-5472.CAN-06-1863 PMID: 17308109
30. Fall-Dickson J.M., Ramsay ES, Castro K, Woltz P., Sportes C. Oral mucositis-related oropharyngeal pain and correlative tumor necrosis factor-alpha expression in adult oncology patients undergoing hematopoietic stem cell transplantation. Clin Ther 2007; 29 Suppl:2547-61.
31. Lalla R.V., Pilbeam CC, Walsh S.J., Sonis ST, Keefe DMK, Peterson DE. Role of the cyclooxygenase pathway in chemotherapy-induced oral mucositis: a pilot study. Support Care Cancer 2010; 18:95-103. doi: 10.1007/s00520-009-0635-1 PMID: 19404685
32. Logan RM, Gibson RJ, Sonis S.T., Keefe DMK. Nuclear factor-kappaB (NF-kappaB) and cyclooxygen-ase-2 (COX-2) expression in the oral mucosa following cancer chemotherapy. Oral Oncol 2007; 43:395-401. doi: 10.1016/j.oraloncology.2006.04.011 PMID: 16979925
33. Yeoh ASJ, Bowen JM, Gibson R.J., Keefe DMK. Nuclear factor kappaB (NFkappaB) and cyclooxygen-ase-2 (Cox-2) expression in the irradiated colorectum is associated with subsequent histopathological changes. Int J Radiat Oncol Biol Phys 2005; 63:1295-1303. doi: 10.1016/j.ijrobp.2005.04.041 PMID: 16099597
34. Srivastava N, Kerr WG Role of inositol poly-phosphatases and their targets in T cell biology. Front Immunol 2013; 4:1-12.
35. Mougeot JLC, Bahrani-Mougeot FK, Lockhart P.B., Brennan MT. Microarray analyses of oral punch biopsies from acute myeloid leukemia (AML) patients treated with chemotherapy. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2013; 112:446-52.
36. Keefe DM, Brealey J, Goland G.J., Cummins AG. Chemotherapy for cancer causes apoptosis that precedes hypoplasia in crypts of the small intestine in humans. Gut 2000; 47:632-7. doi: 10.1136/gut.47.5.632 PMID: 11034578
37. Correale C, Genua M, Vetrano S., Mazzini E, Martinoli C, Spinelli A., et al. Bacterial sensor triggering receptor expressed on myeloid cells-2 regulates the mucosal inflammatory response. Gastroenterol 2013; 144:346-56.e3.
38. Saint-Vis B de, Vincent J, Vandenabeele S, Vanbervliet B, Pin JJ, Ait-Yahia S, et al. A novel lysosome-associated membrane glycoprotein, DC-LAMP, induced upon DC Maturation, is transiently expressed in MHC Class II compartment. Immunity 1998; 9:325-36. PMID: 9768752
39. N'Diaye E.N., Branda CS, Branda S.S., Nevarez L., Colonna M, Lowell C, et al TREM-2 (triggering receptor expressed on myeloid cells 2) is a phagocytic receptor for bacteria. J Cell Biol 2009; 184:215-23. doi: 10.1083/jcb.200808080 PMID: 19171755
40. Aas JA, Paster BJ, Stokes L.N., Olsen I., Dewhirst FE. Defining the Normal Bacterial Flora of the Oral Cavity. J Clin Microbiol 2005; 43:5721-32. doi: 10.1128/JCM.43.11.5721-5732.2005 PMID: 16272510
41. Schlecker E, Fiegler N, Arnold A., Altevogt P, Rose-John S, Moldenhauer G, et al Metalloprotease-mediated tumor cell shedding of B7-H6, the ligand of the natural killer cell-activating receptor NKp30. Cancer Res 2014; 74:3429-40. doi: 10.1158/0008-5472.CAN-13-3017 PMID: 24780758
42. Fijlstra M, Ferdous M, Koning A.M., Rings EHHM, Harmsen HJM, Tissing WJE. Substantial decreases in the number and diversity of microbiota during chemotherapy-induced gastrointestinal mucositis in a rat model. Support Care Cancer 2014; 23:1513-22. doi: 10.1007/s00520-014-2487-6 PMID: 25376667
43. Bergmann OJ. Alterations in oral microflora and pathogenesis of acute oral infections during remission-induction therapy in patients with acute myeloid leukaemia. Scand J Infect Dis 1991; 23:355-66. PMID: 1909053
44. Akiyama M. The roles of ABCA12 in epidermal lipid barrier formation and keratinocyte differentiation. Biochim Biophys Acta 2014; 1841:435-40. doi: 10.1016/j.bbalip.2013.08.009 PMID: 23954554
45. Hui DY, Howles PN Carboxyl ester lipase: structure-function relationship and physiological role in lipoprotein metabolism and atherosclerosis. J Lipid Res 2002; 43:2017-30.
46. Neefjes J, Jongsma MLM, Paul P, Bakke O. Towards a systems understanding of MHC class I and MHC class II antigen presentation. Nat Rev Immunol 2011; 11:823-36. doi: 10.1038/nri3084 PMID: 22076556
47. Hershberg RM, Framson PE, Cho D.H., Lee LY, Kovats S, Beitz J, et al Intestinal epithelial cells use two distinct pathways for HLA class II antigen processing. J Clin Invest 1997; 100:204-15. doi: 10.1172/JCI119514 PMID: 9202073
48. Parkin J, Cohen B. An overview of the immune system. Lancet 2001; 357:1777-89. doi: 10.1016/S0140-6736(00)04904-7 PMID: 11403834
49. Steinman RM, Hemmi H. Dendritic cells: translating innate to adaptive immunity. Curr Top Microbiol Immunol 2006; 311:17-58. In: Pulendran B, Ahmed R, editors. From Innate Immunity to immunological memory. Springer Verlag http://www.springer.com/978-3-540-32635-9
50. Low SK, Takahashi A, Mushiroda T., Kubo M. Genome-wide association study: a usefull tool to identify common genetic variants associated with drug toxicity and efficacy in cancer pharmacogenomics. Clin Cancer Res 2014; 15:2541-52.
51. Goyette P, Boucher G, Mallon D., Ellinghaus E, Jostins L, Huang H., et al. High-density mapping of the MHC identifies a shared role for HLA-DRB1 ∗01:03 in inflammatory bowel diseases and heterozygous advantage in ulcerative colitis. Nat Genet 2015; 47:172-9. doi: 10.1038/ng.3176 PMID: 25559196
52. Parkes M, Cortes A, van Heel DA, Brown MA. Genetic insights into common pathways and complex relationships among immune-mediated diseases. Nat Rev Genet 2013; 14:661-73. doi: 10.1038/nrg3502 PMID: 23917628
53. Stockmann P, Nkenke E, Englbrecht M., Schlittenbauer T, Wehrhan F, Rauh C., et al. Major histocompatibility complex class II polymorphisms are associated with the development of anti-resorptive agent-induced osteonecrosis of the jaw. J Cranio-Maxillofacial Surg 2013; 41:71-75.
54. Chen E. Impact of Addisons disease and psoriasis on the frequency of oral mucositis. Masters thesis, Harward School of Dental Medicine 2003, private copy.
55. Vasku A, Bienertova-Vasku J, Izakovicova-Holla L, Goldbergova MP, Kozacikova Z, Splichal Z., et al. Polymorphisms in HLA-related genes and psoriasis heredity in patients with psoriasis. Int J Dermatol 2013; 52:960-5. doi: 10.1111/ijd.12213 PMID: 23834030
56. ABCA12 - Psoriasis leasion and non-lesional skin http://www.ncbi.nlm.nih.gov/geoprofiles/100696959
57. Al-Dasooqi N., Gibson RJ, Bowen J.M., Keefe DM. Matrix metalloproteinases: key regulators in the pathogenesis of chemotherapy-induced mucositis? Cancer Chemother Pharmacol 2009; 64:1-9. doi: 10.1007/s00280-009-0984-y PMID: 19305997
58. Fleming S, Harrison SJ, Blombery P, Joyce T., Stokes K, Seymour JF, et al The choice of multiple myeloma induction therapy affects the frequency and severity of oral mucositis after melphalan-based autologous stem cell transplantation. Clin Lymphoma, Myeloma Leuk 2014; 14:291-6.
59. Aref S, Azmy E, El-Gilany AH. Upregulation of CD200 is associated with regulatory T cell expansion and disease progression in multiple myeloma. Hematol Oncol 2007; 25:127-131. doi: 10.1002/hon.2206 PMID: 26033514
60. Dorner T, Shock A, Smith KGC. CD22 and Autoimmune Disease. Int Rev Immunol 2012; 31:363-378. doi: 10.3109/08830185.2012.709890 PMID: 23083346
61. Douds JJ, Long DJ, Kim A.S., Li S. Diagnostic and prognostic significance of CD200 expression and its stability in plasma cell myeloma. J Clin Pathol 2014; 67:792-6. doi: 10.1136/jclinpath-2014-202421 PMID: 24958785
62. Lalla R.V., Pilbeam CC, Walsh S.J., Sonis ST, Keefe DMK, Peterson DE. Role of the cyclooxygenase pathway in chemotherapy-induced oral mucositis: a pilot study. Support Care Cancer 2014; 18:95-103.